Ceci L, Han Y, Krutsinger K, Baiocchi L, Wu N, Kundu D, Kyritsi K, Zhou T, Gaudio E, Francis H, et al
Since 2021, semaglutide has also been approved specifically for chronic weight management in adults with a body mass index (BMI) of 27 or greater, those who have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol
The D-Phe stereochemistry and Nle substitution were specifically selected to resist enzymatic proteolysis, as established in the precursor work (Sawyer 1980, PMID 6777774)
The gradual dose escalation schedule is specifically designed to minimise these moving up doses too quickly is the main reason gastrointestinal side effects become difficult to manage
View the full Certificate of Analysis here: A 10mg configuration gives laboratories a defined and manageable format for paired receptor pathway studies